BioSpace News Archive

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced they will participate virtually at conferences during January 2021. 8 January 2021 – Theresa Heggie, Chief Executive Officer, will join a panel – Br

Karyopharm Therapeutics Inc. announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 50,500 shares of Karyopharm’s common stock to 12 newly-hired employees, with a grant date of December 31, 2020.

Scholar Rock announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 5:20 p.m. ET.

Brooks Automation, Inc. announced that company management will participate in two upcoming virtual investor conferences

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced positive topline results from its Phase 2 double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive Chief Executive Officer, J. Christopher Barry will present at the 39 th Annual Virtual J.P. Morgan Healthcare Conference on Wednesd

Akero Therapeutics to Present at the 39 th Annual J.P. Morgan Healthcare Conference

On Wednesday, January 13, 2021, Cardiovascular Systems’ (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, will participate in a fireside chat presentation at the 23rd Annual Needham Virtual Growth Conference at 4:15 p.m. Eastern Time.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Officer, Dr. Gerrit Dispersyn , will present at the upcoming H.C. Wainwright Bi

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 4:30 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.